Abstract
The enzyme indoleamine 2,3-dioxygenase (IDO) regulates immune responses through the capacity to degrade the essential amino acid tryptophan into kynurenine and other downstream metabolites that suppress effector T-cell function and favour the differentiation of regulatory T cells. Considerable experimental evidence indicates that IDO can be expressed by dendritic cells, by tumour cells or by surrounding stromal cells, either within proximity of the tumour or at distal sites. Recent advances in the biochemistry of IDO and in our understanding of the biological relevance of IDOmediated tryptophan consumption to the establishment of dominant immune tolerance to cancer will be summarised and discussed. Within the wider context of cancer immunotherapy, this Review also delineates how IDO could be exploited as a molecular target for therapeutic intervention in order to boost anti-cancer immunity.
Keywords: Indoleamine 2,3-dioxygenase, immune tolerance, regulatory T cell, haematopoietic growth factors, cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Volume: 9 Issue: 2
Author(s): S. Rutella, G. Bonanno and R. De Cristofaro
Affiliation:
Keywords: Indoleamine 2,3-dioxygenase, immune tolerance, regulatory T cell, haematopoietic growth factors, cancer
Abstract: The enzyme indoleamine 2,3-dioxygenase (IDO) regulates immune responses through the capacity to degrade the essential amino acid tryptophan into kynurenine and other downstream metabolites that suppress effector T-cell function and favour the differentiation of regulatory T cells. Considerable experimental evidence indicates that IDO can be expressed by dendritic cells, by tumour cells or by surrounding stromal cells, either within proximity of the tumour or at distal sites. Recent advances in the biochemistry of IDO and in our understanding of the biological relevance of IDOmediated tryptophan consumption to the establishment of dominant immune tolerance to cancer will be summarised and discussed. Within the wider context of cancer immunotherapy, this Review also delineates how IDO could be exploited as a molecular target for therapeutic intervention in order to boost anti-cancer immunity.
Export Options
About this article
Cite this article as:
Rutella S., Bonanno G. and De Cristofaro R., Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187153009788452453
DOI https://dx.doi.org/10.2174/187153009788452453 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological Actions and Metabolism of Currently Used Pharmacological Agents for the Treatment of Congestive Heart Failure
Current Drug Metabolism Emerging Potential of Citrus Flavanones as an Antioxidant in Diabetes and its Complications
Current Topics in Medicinal Chemistry Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology Evaluation of Cardiac Scan in Diagnosing Coronary-artery Disease
Current Medical Imaging Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry PREFACE: Cardiovascular and Hematological Medicine in 2015 - Advances and Insights
Cardiovascular & Hematological Agents in Medicinal Chemistry The HGF/c-Met Receptor System Under Pathological Conditions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Indications for Implantable Cardioverter Defibrillators in Non-Ischemic Cardiomyopathies and Channelopathies
Reviews on Recent Clinical Trials Self Managing Heart Failure in Remote Australia - Translating Concepts into Clinical Practice
Current Cardiology Reviews Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets